Molecular Partners Balance Sheet Health

Financial Health criteria checks 6/6

Molecular Partners has a total shareholder equity of CHF138.8M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF154.2M and CHF15.4M respectively.

Key information

0%

Debt to equity ratio

CHF 0

Debt

Interest coverage ration/a
CashCHF 143.62m
EquityCHF 138.78m
Total liabilitiesCHF 15.43m
Total assetsCHF 154.21m

Recent financial health updates

Recent updates

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09
Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23
Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31
What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09
Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26
Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24
We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09
Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Feb 10
Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Jan 21
Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Financial Position Analysis

Short Term Liabilities: MOLN's short term assets (CHF149.5M) exceed its short term liabilities (CHF10.4M).

Long Term Liabilities: MOLN's short term assets (CHF149.5M) exceed its long term liabilities (CHF5.0M).


Debt to Equity History and Analysis

Debt Level: MOLN is debt free.

Reducing Debt: MOLN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOLN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MOLN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 1.7% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 20:20
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Molecular Partners AG is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jo WaltonCredit Suisse
null nullCredit Suisse
Thomas KaufmannCredit Suisse